Histone deacetylase inhibitor-temozolomide co-treatment inhibits melanoma growth through suppression of Chemokine (C-C motif) ligand 2-driven signals

Laura Gatti, Alexandra Sevko, Michelandrea de Cesare, Noemi Arrighetti, Giacomo Manenti, Emilio Ciusani, Paolo Verderio, Chiara M. Ciniselli, Denis Cominetti, Nives Carenini, Elisabetta Corna, Nadia Zaffaroni, Monica Rodolfo, Licia Rivoltini, Viktor Umansky, Paola Perego

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Target-specific agents used in melanoma are not curative, and chemokines are being implicated in drug-resistance to target-specific agents. Thus, the use of conventional agents in rationale combinations may result in optimization of therapy. Because histone deacetylases participate in tumor development and progression, the combination of the pan-inhibitor SAHA and temozolomide might provide a therapeutic advantage. Here, we show synergism between the two drugs in mutant BRAF cell lines, in association with decreased phosphorylation of cell survival proteins (e.g., C-Jun-N-terminal-kinase, JNK). In the spontaneous ret transgenic mouse melanoma model, combination therapy produced a significant disease onset delay and down-regulation of Chemokine (C-C motif) ligand 2 (CCL2), JNK, and of Myeloid-derived suppressor cell recruitment. Co-incubation with a CCL2-blocking-antibody enhanced in vitro cell sensitivity to temozolomide. Conversely, recombinant CCL2 activated JNK in human tumor melanoma cells. In keeping with these results, the combination of a JNK-inhibitor with temozolomide was synergistic. By showing that down-regulation of CCL2-driven signals by SAHA and temozolomide via JNK contributes to reduce melanoma growth, we provide a rationale for the therapeutic advantage of the drug combination. This combination strategy may be effective because of interference both with tumor cell and tumor microenvironment.

Original languageEnglish
Pages (from-to)4516-4528
Number of pages13
JournalOncotarget
Volume5
Issue number12
Publication statusPublished - 2014

Fingerprint

temozolomide
Histone Deacetylase Inhibitors
Chemokine CCL2
Melanoma
Phosphotransferases
Growth
Ligands
Down-Regulation
Cellular Microenvironment
Neoplasms
Blocking Antibodies
Histone Deacetylases
Tumor Microenvironment
Drug Combinations
Therapeutics
Protein C
Chemokines
Drug Resistance
Transgenic Mice
Cell Survival

Keywords

  • CCL2
  • Histone deacetlylase inhibition
  • JNK
  • Melanoma
  • Temozolomide

ASJC Scopus subject areas

  • Oncology
  • Medicine(all)

Cite this

Histone deacetylase inhibitor-temozolomide co-treatment inhibits melanoma growth through suppression of Chemokine (C-C motif) ligand 2-driven signals. / Gatti, Laura; Sevko, Alexandra; de Cesare, Michelandrea; Arrighetti, Noemi; Manenti, Giacomo; Ciusani, Emilio; Verderio, Paolo; Ciniselli, Chiara M.; Cominetti, Denis; Carenini, Nives; Corna, Elisabetta; Zaffaroni, Nadia; Rodolfo, Monica; Rivoltini, Licia; Umansky, Viktor; Perego, Paola.

In: Oncotarget, Vol. 5, No. 12, 2014, p. 4516-4528.

Research output: Contribution to journalArticle

@article{4d93ecc37cf54302bd0a3e3878cf133c,
title = "Histone deacetylase inhibitor-temozolomide co-treatment inhibits melanoma growth through suppression of Chemokine (C-C motif) ligand 2-driven signals",
abstract = "Target-specific agents used in melanoma are not curative, and chemokines are being implicated in drug-resistance to target-specific agents. Thus, the use of conventional agents in rationale combinations may result in optimization of therapy. Because histone deacetylases participate in tumor development and progression, the combination of the pan-inhibitor SAHA and temozolomide might provide a therapeutic advantage. Here, we show synergism between the two drugs in mutant BRAF cell lines, in association with decreased phosphorylation of cell survival proteins (e.g., C-Jun-N-terminal-kinase, JNK). In the spontaneous ret transgenic mouse melanoma model, combination therapy produced a significant disease onset delay and down-regulation of Chemokine (C-C motif) ligand 2 (CCL2), JNK, and of Myeloid-derived suppressor cell recruitment. Co-incubation with a CCL2-blocking-antibody enhanced in vitro cell sensitivity to temozolomide. Conversely, recombinant CCL2 activated JNK in human tumor melanoma cells. In keeping with these results, the combination of a JNK-inhibitor with temozolomide was synergistic. By showing that down-regulation of CCL2-driven signals by SAHA and temozolomide via JNK contributes to reduce melanoma growth, we provide a rationale for the therapeutic advantage of the drug combination. This combination strategy may be effective because of interference both with tumor cell and tumor microenvironment.",
keywords = "CCL2, Histone deacetlylase inhibition, JNK, Melanoma, Temozolomide",
author = "Laura Gatti and Alexandra Sevko and {de Cesare}, Michelandrea and Noemi Arrighetti and Giacomo Manenti and Emilio Ciusani and Paolo Verderio and Ciniselli, {Chiara M.} and Denis Cominetti and Nives Carenini and Elisabetta Corna and Nadia Zaffaroni and Monica Rodolfo and Licia Rivoltini and Viktor Umansky and Paola Perego",
year = "2014",
language = "English",
volume = "5",
pages = "4516--4528",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "12",

}

TY - JOUR

T1 - Histone deacetylase inhibitor-temozolomide co-treatment inhibits melanoma growth through suppression of Chemokine (C-C motif) ligand 2-driven signals

AU - Gatti, Laura

AU - Sevko, Alexandra

AU - de Cesare, Michelandrea

AU - Arrighetti, Noemi

AU - Manenti, Giacomo

AU - Ciusani, Emilio

AU - Verderio, Paolo

AU - Ciniselli, Chiara M.

AU - Cominetti, Denis

AU - Carenini, Nives

AU - Corna, Elisabetta

AU - Zaffaroni, Nadia

AU - Rodolfo, Monica

AU - Rivoltini, Licia

AU - Umansky, Viktor

AU - Perego, Paola

PY - 2014

Y1 - 2014

N2 - Target-specific agents used in melanoma are not curative, and chemokines are being implicated in drug-resistance to target-specific agents. Thus, the use of conventional agents in rationale combinations may result in optimization of therapy. Because histone deacetylases participate in tumor development and progression, the combination of the pan-inhibitor SAHA and temozolomide might provide a therapeutic advantage. Here, we show synergism between the two drugs in mutant BRAF cell lines, in association with decreased phosphorylation of cell survival proteins (e.g., C-Jun-N-terminal-kinase, JNK). In the spontaneous ret transgenic mouse melanoma model, combination therapy produced a significant disease onset delay and down-regulation of Chemokine (C-C motif) ligand 2 (CCL2), JNK, and of Myeloid-derived suppressor cell recruitment. Co-incubation with a CCL2-blocking-antibody enhanced in vitro cell sensitivity to temozolomide. Conversely, recombinant CCL2 activated JNK in human tumor melanoma cells. In keeping with these results, the combination of a JNK-inhibitor with temozolomide was synergistic. By showing that down-regulation of CCL2-driven signals by SAHA and temozolomide via JNK contributes to reduce melanoma growth, we provide a rationale for the therapeutic advantage of the drug combination. This combination strategy may be effective because of interference both with tumor cell and tumor microenvironment.

AB - Target-specific agents used in melanoma are not curative, and chemokines are being implicated in drug-resistance to target-specific agents. Thus, the use of conventional agents in rationale combinations may result in optimization of therapy. Because histone deacetylases participate in tumor development and progression, the combination of the pan-inhibitor SAHA and temozolomide might provide a therapeutic advantage. Here, we show synergism between the two drugs in mutant BRAF cell lines, in association with decreased phosphorylation of cell survival proteins (e.g., C-Jun-N-terminal-kinase, JNK). In the spontaneous ret transgenic mouse melanoma model, combination therapy produced a significant disease onset delay and down-regulation of Chemokine (C-C motif) ligand 2 (CCL2), JNK, and of Myeloid-derived suppressor cell recruitment. Co-incubation with a CCL2-blocking-antibody enhanced in vitro cell sensitivity to temozolomide. Conversely, recombinant CCL2 activated JNK in human tumor melanoma cells. In keeping with these results, the combination of a JNK-inhibitor with temozolomide was synergistic. By showing that down-regulation of CCL2-driven signals by SAHA and temozolomide via JNK contributes to reduce melanoma growth, we provide a rationale for the therapeutic advantage of the drug combination. This combination strategy may be effective because of interference both with tumor cell and tumor microenvironment.

KW - CCL2

KW - Histone deacetlylase inhibition

KW - JNK

KW - Melanoma

KW - Temozolomide

UR - http://www.scopus.com/inward/record.url?scp=84905097439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905097439&partnerID=8YFLogxK

M3 - Article

C2 - 24980831

AN - SCOPUS:84905097439

VL - 5

SP - 4516

EP - 4528

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 12

ER -